Related Experiment Video

Updated: Jun 9, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Association between the -1562 C/T MMP-9 polymorphism and cerebrovascular disease in a Polish population

Piotr Szczudlik1, Anna Borratyńska

  • 1Klinika Neurologii, Warszawski Uniwersytet Medyczny, ul. Banacha 1a, 00-097 Warszawa, Poland. pszczudlik@wum.edu.pl

Neurologia I Neurochirurgia Polska
|September 10, 2010
PubMed
Abstract

Insights

This study found no link between the MMP-9 -1562 C/T gene variant and cerebrovascular diseases like stroke in the Polish population. The MMP-9 polymorphism does not appear to increase the risk for these conditions.

Area of Science:

  • Genetics and Molecular Biology
  • Neurology
  • Cardiovascular Research

Background:

  • Matrix metalloproteinase 9 (MMP-9) degrades extracellular matrix, crucial in vascular pathology.
  • The MMP-9 -1562 C/T polymorphism influences enzymatic activity, potentially affecting cerebrovascular disease risk.
  • Previous research suggests a link between MMP-9 activity and vascular diseases.

Purpose of the Study:

  • To investigate the association between the MMP-9 -1562 C/T polymorphism and cerebrovascular disease risk.
  • To determine if this genetic variation is a significant risk factor for stroke in a Polish population.

Main Methods:

  • A case-control study involving 775 patients with cerebrovascular disease (ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage) and 766 matched controls.
  • Polymerase chain reaction (PCR) and restricted enzyme digestion were used to analyze the MMP-9 -1562 C/T polymorphism.
  • Statistical analysis compared genotype and allele frequencies between patient and control groups.

Main Results:

  • No statistically significant difference was observed in the frequencies of CC, CT, or TT genotypes of the MMP-9 -1562 C/T polymorphism between patients and controls.
  • Analysis of C and T allele frequencies also revealed no significant association with ischaemic stroke, intracerebral haemorrhage, or subarachnoid haemorrhage.
  • The study did not find evidence supporting the MMP-9 polymorphism as a risk factor for the studied cerebrovascular diseases.

Conclusions:

  • The -1562 C/T polymorphism of MMP-9 is not associated with ischaemic stroke in the studied Polish population.
  • No significant link was found between this MMP-9 polymorphism and subarachnoid haemorrhage or spontaneous intracerebral haemorrhage.
  • These findings suggest that the MMP-9 -1562 C/T polymorphism may not play a significant role in the pathogenesis of major cerebrovascular events in this population.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...